Treatment of Chronic Hepatitis C in Confirmed Acute HCV Infection (HCV RNA-Positive)

This protocol addresses chronic hepatitis C management specifically in persons who have a confirmed acute hepatitis C infection — identified by a positive HCV RNA result. Current guidance supports prompt treatment in this population rather than a period of watchful waiting.

Clinical Scenario

Acute hepatitis C | HCV RNA-positive

The population here is defined by a confirmed acute HCV infection with detectable HCV RNA. The recommended approach is a test-and-treat strategy — proceeding directly to treatment without awaiting possible spontaneous clearance of the virus.

Treatment Approach (Partial Overview)

Persons with confirmed acute HCV infection are managed with a full-duration direct-acting antiviral (DAA) regimen — the same approach applied in chronic HCV infection. An abbreviated treatment course is not part of the recommended strategy for this scenario.

The complete regimen selection, decision algorithm, and sequencing details are in the full structured protocol below.

Treatment Goal

The primary clinical target is sustained virologic response 12 weeks after completion of therapy (SVR12) — defined as undetectable HCV RNA at that time point.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciad319

The Guidance Panel reiterates the recommendation that persons with confirmed acute HCV infection (HCV RNA–positive) should be treated the same as those with chronic HCV infection without awaiting possible spontaneous clearance (ie, a test-and-treat approach).
As such, an abbreviated course of DAA therapy is not recommended for acute HCV infection.
SVR12, sustained virologic response 12 weeks after completion of therapy.

View source ↗